SENS-AI
REM Results Neutral

REMGRO LIMITED - Summary of audited results for the year ended 30 June 2026 and cash dividend declarations

Remgro Limited
Full analysis

What this filing means

A strong year, but one the market had already been told about. Remgro's audited FY2026 results show HEPS up 42.2% to R20.03 — landing in the upper half of the R19.30–R20.71 range guided just seven days earlier — alongside a 73% ordinary dividend hike to 595 cents and a 550 cent special dividend. The headline number is flattered by R1 023 million of once-off items, while total earnings collapsed 56.5% on a R10 042 million Mediclinic Switzerland impairment.

Remgro made much more profit per share than last year and is paying shareholders a much bigger dividend — that is genuinely good. But the company told everyone to expect this a week ago, so the earnings number itself is not new information. The catch is that the profit number includes some one-off windfalls, and the full-year profit actually fell sharply because of a big write-down at Mediclinic. So the dividend is the strongest signal here, not the earnings growth.

Bull case

  • HEPS of R20.03 landed within the guided R19.30–R20.71 range, with the 42.2% YoY gain sitting at approximately the midpoint of the prior 37%–47% guide — consistent with the met-not-beaten framing of these results.
  • Headline earnings rose 42.3% to R11 140m, driven by broad-based operational improvement across Mediclinic, Rainbow Chicken, CIVH, OUTsurance and Heineken Beverages.
  • Ordinary DPS jumped 73.0% to 595 cents, signalling a sharp step-up in payout discipline.
  • Adjusted FCFC per share rose 28.6% to R8.91, with ordinary dividends received up 23.8% to R4 558m, evidencing underlying cash-generation quality.
  • A 550 cent special dividend has been declared alongside the ordinary final dividend, subject to SARB approval.

Bear case

  • EPS collapsed 56.5% to R2.59, driven by Remgro's R10 042 million share of Mediclinic's Switzerland asset and business impairments — total earnings more than halved.
  • Reported 42.2% HEPS growth includes R1 023 million of once-off items (Mediclinic tax benefit R511m, tariff release R294m, TotalEnergies refund R218m); adjusted growth ~29%.
  • The 550 cents per share special dividend remains conditional on South African Reserve Bank approval — a binary risk on this material capital return.
  • Missing evidence: the filing provides no FY2027 outlook, so investors cannot assess whether the implied momentum is sustainable or whether FY2026 was a peak against the prior R10 042m Mediclinic drag.
  • Missing evidence: the summary results omit detailed balance sheet and net debt figures, limiting ability to verify the capital adequacy behind the combined 1 145 cents per share dividend declarations.
View original SENS announcement

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

A solid result that confirms what the market was already told: HEPS landed in the upper half of the guided range, and the 73% ordinary dividend hike plus a 550 cent special dividend. But the earnings quality is mixed — R1 023 million of once-offs flatter the headline, and total earnings more than halved on the Mediclinic impairment. The guidance bar was met, not beaten, so this is validation for an existing view rather than a fresh conviction signal. So what: the dividend step-up is the strongest signal, but the market still needs the full AFS to verify the balance-sheet strength behind it and any FY2027 outlook to judge sustainability.

The full AFS and the SARB decision on the special dividend are the next disclosures that will settle whether the payout is durable.

Evidence from the filing

  • EPS collapsed 56.5% to R2.59, driven by Remgro's R10 042 million share of Mediclinic's Switzerland asset and business impairments — total earnings more than halved.

    “Earnings per share: down by 56.5% to R2.59”

  • Reported 42.2% HEPS growth includes R1 023 million of once-off items (Mediclinic tax benefit R511m, tariff release R294m, TotalEnergies refund R218m); adjusted growth ~29%.

    “The headline earnings growth of 42.3% includes material once-off items amounting to R1 023 million, comprising Mediclinic's Switzerland tax benefit of R511 million and tariff provision release of R294 million, as well as TotalEnergies' Transnet pipeline cost refund of R218 million.”

  • The 550 cents per share special dividend remains conditional on South African Reserve Bank approval — a binary risk on this material capital return.

    “The special dividend is subject to South African Reserve Bank approval”

  • HEPS of R20.03 landed within the guided R19.30–R20.71 range and sits in the upper half, with the 42.2% YoY gain tracking the upper portion of the 37%–47% guide.

    “Headline earnings per share: up by 42.2% to R20.03”

  • Headline earnings rose 42.3% to R11 140m, driven by broad-based operational improvement across Mediclinic, Rainbow Chicken, CIVH, OUTsurance and Heineken Beverages.

    “Headline earnings increased by 42.3% from R7 827 million to R11 140 million”

  • Ordinary DPS jumped 73.0% to 595 cents, signalling a sharp step-up in payout discipline.

    “Ordinary dividend per share: up by 73.0% to 595 cents”

  • Adjusted FCFC per share rose 28.6% to R8.91, with ordinary dividends received up 23.8% to R4 558m, evidencing underlying cash-generation quality.

    “adjusted FCFC per share increased by 28.6% to R8.91 (2025: R6.93)”

  • A 550 cent special dividend has been declared alongside the ordinary final dividend, subject to SARB approval.

    “special dividend of 550 cents per share”
Category
Results
Event posture
Constructive
Published
Sep 18, 2026

More on Remgro Limited

Remgro Limited (REM) share price All Remgro Limited SENS announcements

Related filings